NEWS

NCODA Spring Forum 2020 Transitions to Virtual E-Meeting March 10, 2020 3pm Eastern To our valued members and corporate partners, In alignment with our Guiding Values, 1) Patient-Centered and 2) Always Collaborative, NCODA is taking all necessary precautions in order to provide our members and corporate partners a value-added experience, while remaining vigilant concerning the […]

BRIDGEWATER, N.J., March 2, 2020 /PRNewswire/ — The U.S. Food and Drug Administration (FDA) has approved Sarclisa® (isatuximab-irfc) in combination with pomalidomide and dexamethasone (pom-dex) for the treatment of adults with relapsed refractory multiple myeloma (RRMM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor. Sarclisa is expected to be available to patients […]

MISSION STATEMENT/PHILOSOPHY: Shenandoah Oncology exists to provide comprehensive, compassionate care to our patients.  It is our goal to offer the most current, state-of-the art oncology and hematology care.  We will offer clinical trials, oral and IV indigent drug programs, and other ancillary services. LOCATION(S): Shenandoah Oncology has one office located in Winchester, Virginia.  We serve […]

MISSION STATEMENT/PHILOPSOPHY: Our mission is to provide individualized treatment, utilizing the best technical approach, and recognizing each patient’s psychological, emotional, and spiritual needs during their journey with their illness and healing. For more than 25 years, Gettysburg Cancer Center has been committed to providing cancer care in a community-based setting close to home. Our all-encompassing […]

MISSION STATEMENT/PHILOPSOPHY: To provide high quality, cost-effective health care that delivers the best value to the people we serve in a spiritual environment of caring in association with internationally recognized teaching and research. LOCATION(S): Houston Methodist Hospital Texas Medical Center PRACTICE DETAILS: 12 Physicians: Medical oncology, breast oncologist and hematologists. 5 medical oncologist on their […]

The US Food and Drug Administration (FDA) has approved CALQUENCE® (acalabrutinib) capsules for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).[i] CALQUENCE for CLL was granted Breakthrough Therapy Designation by the FDA, and the approval was granted under the FDA’s Real Time Oncology Review (RTOR) and newly established Project Orbis […]

MISSION STATEMENT/PHILOPSOPHY: In collaboration with our academic partners, our mission is to advance healthcare to improve the health of our patients and communities, promote health equity and develop the next generations of healthcare leaders. LOCATION(S): Chicago’s west side PRACTICE DETAILS: 465 bed Hospital, 7 Health Science Colleges Heme/Onc 19 chair outpatient infusion center, 13 attendings, […]

Bristol-Myers Squibb’s study met its co-primary endpoint of overall survival with Opdivo® (nivolumab) plus low dose Yervoy® (ipilimumab) vs. chemotherapy in first-line Non-Small Cell Lung Cancer patients whose tumors expressed PD-L1 ≥1%. This is the third tumor type in which Opdivo plus Yervoy demonstrates overall survival benefit in a Phase 3 Trial. Learn more HERE

AstraZeneca’s trastuzumab deruxtecan was granted FDA Priority Review for treatment of patients with HER2-positive metastatic breast cancer.Trastuzumab deruxtecan has the potential to transform the treatment landscape for patients with HER2-positive metastatic breast cancer who have limited treatment options today. Learn more at: https://www.astrazeneca.com/media-centre/press-releases/2019/trastuzumab-deruxtecan-granted-fda-priority-review-for-treatment-of-patients-with-her2-positive-metastatic-breast-cancer-17102019.html

LOS ANGELES, Calif., Oct. 2, 2019 – Puma Biotechnology, Inc. (NASDAQ: PBYI) announced that the U.S. Food and Drug Administration (FDA) has approved a labeling supplement for NERLYNX® (neratinib) for the extended adjuvant treatment of HER2-positive early stage breast cancer. With the approval of the labeling supplement, the label now includes safety information based on […]